Abstract: A dispensing device includes a first dispensing box and a second dispensing box. The first dispensing box is provided with a water inlet channel. The dispensing device further includes a flushing pipeline. The water inlet of the flushing pipeline is connected to the water outlet of the water inlet channel, and the water outlet is connected to the water inlet of the second dispensing box. A laundry treatment device includes a housing, an upper water drum and a lower water drum arranged in the housing, and a dispensing device. A first dispensing box and a second dispensing box are arranged above the upper water drum, a liquid outlet of the second dispensing box is connected to a liquid inlet of the first dispensing box, and a liquid outlet of the first dispensing box is respectively connected to the upper water drum and the lower water drum.

Abstract: Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Abstract: A liquid storage box, an additive dispensing apparatus, and a method for identifying an additive type. The liquid storage box is provided with a closed chamber for storing additive. At least one marking conductive component is disposed on the liquid storage box. Any one element or a combination of elements selected from a group consisting of the quantity, position, shape, and resistance of the marking conductive components provided on the liquid storage box indicates correspondingly the type of additive. The identification conductive components are arranged in an accommodating portion of the additive dispensing apparatus. The identification conductive components cover the shadows of the marking conductive components disposed on different liquid storage boxes in the accommodation portion. The marking conductive component of the liquid storage box is spaced from the identification conductive component in the accommodating portion, so as to form capacitance correspondingly indicating the type of the additive.

Abstract: Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Abstract: A clothes drying device, including an air channel, an air path switching assembly, multiple clothes drying apparatuses, and multiple heating apparatuses. The air path switching assembly includes a first multi-position switching component and a second multi-position switching component. The first multi-position switching component and the second multi-position switching component are respectively provided between a hot air input section and intermediate heat source sections and between a hot air output section and the intermediate heat source sections; the first multi-position switching component and the second multi-position switching component have the same number of switching positions and are configured to work in conjunction to each other so that at least one clothes drying apparatus is selectively communicated with the corresponding hot air input section, the hot air output section, and the intermediate heat source sections so as to form a circulation loop.

Abstract: Provided are methods for treating hematologic malignancy, especially AML-MRC, MDS and/or MM. Specifically, provided are methods for treating AML-MRC and MDS with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as 5-azacitidine or cytarabine, and treating MM with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as pomalidomide, thalidomide, lenalidomide, and/or dexamethasone.

Abstract: The present disclosure pertains to the field of biomedicine, and specifically relates to a method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and optionally a therapeutically effective amount of a tubulin inhibitor. The present disclosure further relates to a pharmaceutical composition or kit comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and optionally a tubulin inhibitor.

Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

Abstract: A liquid storage box, an additive dispensing apparatus, and a method for identifying an additive type. The liquid storage box is provided with a closed chamber for storing additive. At least one marking conductive component is disposed on the liquid storage box. Any one element or a combination of elements selected from a group consisting of the quantity, position, shape, and resistance of the marking conductive components provided on the liquid storage box box indicates correspondingly the type of additive. The identification conductive components are arranged in an accommodating portion of the additive dispensing apparatus. The identification conductive components cover the shadows of the marking conductive components disposed on different liquid storage boxes in the accommodation portion.

Abstract: A heating device of a clothes drying treatment device executes an on or off operation in a temperature interval. When the temperature in a drum reaches an upper limit value TDx of the temperature interval under an action of the heating device, the heating device is turned off and the heating device stops heating. The upper limit value TDx decreases as a number of off times x of the heating device increases. Accordingly, a higher initial off temperature is adopted for the heating device, the temperature in the drum rapidly increases to the drying temperature, a preheating time is shortened, and a certain coefficient is multiplied in following control parameters controlling on or off of the heating device. The coefficient is related to the number of on-off times, and the effect is achieved that the off temperature of the clothes dryer gradually decreases as the number of on-off times increases.

Abstract: A method and an apparatus for controlling a door of a washing machine, a device and a storage medium. The method includes: receiving a first opening instruction sent by a first terminal device; setting a door in a to-be-opened state according to the first opening instruction; and receiving a second opening instruction input by a user, and controlling, according to the second opening instruction, the door in the to-be-opened state to open.

Abstract: The present invention relates to one or more combination treatments of cancer patients with a compound of formula (I), and an allosteric inhibitor or an immune checkpoint molecule, wherein R1 and R2 are as described herein.

Abstract: Provided herein in the biomedical field are a pharmaceutical composition, use thereof for treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiting its metastasis in an individual, and a method for treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiting its metastasis in an individual. The method comprises administering to the individual a therapeutically effective amount of an ALK inhibitor, and a therapeutically effective amount of one or more other anticancer reagents. It also relates to a kit comprising an ALK inhibitor, and one or more other anticancer reagents.

Abstract: A clothes drying device, including an air channel, an air path switching assembly, multiple clothes drying apparatuses, and multiple heating apparatuses. The air path switching assembly includes a first multi-position switching component and a second multi-position switching component. The first multi-position switching component and the second multi-position switching component are respectively provided between a hot air input section and intermediate heat source sections and between a hot air output section and the intermediate heat source sections; the first multi-position switching component and the second multi-position switching component have the same number of switching positions and are configured to work in conjunction to each other so that at least one clothes drying apparatus is selectively communicated with the corresponding hot air input section, the hot air output section, and the intermediate heat source sections so as to form a circulation loop.

Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor, an anti-CD20 antibody and/or bendamustine or a combination product comprising a Bcl-2 inhibitor and CHOP, the combination product provides a use of the combination product for prevention and/or treatment of a disease (e.g., cancer, rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis).

Abstract: The present invention relates to a combination product comprising a Bcl-2 inhibitor and a chemotherapeutic agent, and the combination product provides a use in the prevention and/or treatment of diseases (e.g., cancer).

Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor (or a Bc1-2/Bc1-xl dual inhibitor) and a BTK inhibitor, the combination product providing a use in the prevention and/or treatment of a disease (e.g., cancer, autoimmune disease and inflammatory disease.).

Abstract: The present invention pertains to the biomedical field, and particularly relates to a method for treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiting its metastasis in an individual. The method comprises administering to the individual a therapeutically effective amount of one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and a therapeutically effective amount of an EGFR inhibitor. The invention also relates to a pharmaceutical composition or kit comprising one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and an EGFR inhibitor.

Abstract: Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.